AJM onlineClinical research studyRacial, Social, and Clinical Determinants of Hepatocellular Carcinoma Surveillance
Section snippets
Study Population
We conducted a retrospective cohort study of cirrhotic patients followed at Parkland Health and Hospital System, the safety-net system for Dallas County. Parkland is an integrated system with 11 primary care provider clinics in low-income neighborhoods, a multidisciplinary hepatology outpatient clinic, and a tertiary hospital—all sharing 1 electronic medical record system. Parkland provides inpatient and outpatient care for most cirrhotic patients and approximately 50% of hepatocellular
Patient Characteristics
We identified 904 patients with cirrhosis who met inclusion criteria. The median age of patients was 54.8 years (range, 21.0-84.2), and 592 (65%) were men. Our population was racially diverse; 22% were African Americans, 36% were non-Hispanic Caucasians, and 40% were Hispanic Caucasians. Approximately 43% of patients were uninsured/underinsured, 53% of patients had Medicare or Medicaid, and only 4% of patients had private health insurance. The most common causes of cirrhosis were hepatitis C
Discussion
Although a meta-analysis found that less than 20% of patients in the United States undergo hepatocellular carcinoma surveillance,11 the estimate was limited by heterogeneity of operational definitions for surveillance. Clear consistent definitions and measures are necessary to interpret and quantify hepatocellular carcinoma surveillance rates.21 To the best of our knowledge, our study is the first to report guideline-adherent surveillance rates in a large cohort, with approximately 1000
Conclusions
We believe this is the first study to report guideline-consistent surveillance rates among a large cohort of racially and socioeconomically diverse patients. We found only 13% of patients had annual surveillance and only 1.7% had consistent biannual surveillance. Furthermore, we found racial and socioeconomic disparities in receipt of inconsistent surveillance, with significantly lower rates among African Americans and underinsured patients. Studies are needed to explore the reasons for
References (31)
- et al.
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis
Gastroenterology
(2007) - et al.
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis
Clin Gastroenterol Hepatol
(2010) - et al.
Influence of direct referrals on time to diagnosis after an abnormal breast screening result
Cancer Detect Prev
(2004) - et al.
Racial differences in survival of hepatocellular carcinoma in the United States: a population-based study
Clin Gastroenterol Hepatol
(2006) - et al.
Improving hepatocellular carcinoma screening: applying lessons from colorectal cancer screening
Clin Gastroenterol Hepatol
(2013) - et al.
Recent advances in the treatment of hepatocellular carcinoma
Curr Opin Gastroenterol
(2013) - et al.
Early Detection, Curative Treatment, and Survival Rates for HCC Surveillance in Patients with Cirrhosis: A meta-analysis
PLOS Medicine
(2014) - et al.
An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data
Liver Transpl
(2009) - et al.
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials
Hepatology
(1999) - et al.
Management of hepatocellular carcinoma: an update
Hepatology
(2010)
Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis
Aliment Pharmacol Ther
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States
Ann Intern Med
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States
Hepatology
Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review
J Gen Intern Med
Race, ethnicity, and socioeconomic status influence the survival of patients with hepatocellular carcinoma in the United States
Cancer
Cited by (124)
Hepatocellular Carcinoma Surveillance Patterns and Outcomes in Patients With Cirrhosis
2024, Clinical Gastroenterology and HepatologyHepatocellular Carcinoma Surveillance: Evidence-Based Tailored Approach
2024, Surgical Oncology Clinics of North AmericaInsurance Status Correlates with Access to Procedural Therapy for Patients with Early-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study of the National Cancer Database
2023, Journal of Vascular and Interventional RadiologyNeighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas
2023, Clinical Gastroenterology and HepatologyHealthcare Disparities in Interventional Radiology
2022, Journal of Vascular and Interventional RadiologyMulticenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance
2022, Clinical Gastroenterology and Hepatology
Funding: Research reported in this publication was conducted with support from the National Center for Advancing Translational Sciences of the National Institutes of Health under award numbers KL2TR001103 and UL1TR001105, the ACG Junior Faculty Development Award, and the American Cancer Society and Simmons Cancer Center Grant ACS-IRG-02-196 awarded to AGS. The content is solely the responsibility of the authors and does not necessarily represent the official views of UT Southwestern Medical Center and its affiliated health care centers or the NIH.
Conflict of Interest: None.
Authorship: All authors had access to the data and played a role in writing this manuscript.